Charles-Antoine Guay

Charles-Antoine Guay

Auto-generated profile, based on publicly available information

Charles-Antoine Guay

Centre de Recherche de l’Institut Universitaire de Cardiologie et de Pneumologie de Québec - Université Laval , Québec City, Québec

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 October 2023 in Clinical Infectious Diseases
Verified
Journal Article
Closed access
PDF file
SCSara Carazo
Sara Carazo
CGCharles-Antoine Guay
Charles-Antoine Guay
DSDanuta M Skowronski
Danuta M Skowronski
RARachid Amini
Rachid Amini
HCHugues Charest
Hugues Charest
RGRodica Gilca
Rodica Gilca
Background: Influenza immunization programs aim to reduce the risk and burden of severe outcomes. To inform optimal program strategies, we monitored influenza hospitalizations over 7 seasons, stratified by age, comorbidity, and vaccination status. Methods: We assembled data from 4 hospitals involved in an active surveillance network with systematic collection of nasal samples and polymerase chain reaction testing for influenza virus in all patients admitted through the emergency department with acute respiratory infection during the 2012–2013 to 2018–2019 influenza seasons in Quebec, Canada. We estimated seasonal, population-based incidence of influenza-associated hospitalizations by subtype predominance, age, comorbidity, and vaccine status, and derived the number needed to vaccinate to prevent 1 hospitalization per stratum. Results: The average seasonal incidence of influenza-associated hospitalization was 89/100 000 (95% confidence interval, 86–93), lower during A(H1N1) (49–82/100 000) than A(H3N2) seasons (73–143/100 000). Overall risk followed a J-shaped age pattern, highest among infants 0–5 months and adults ≥75 years old. Hospitalization risks were highest for children <5 years old during A(H1N1) but for highest adults aged ≥75 years during A(H3N2) seasons. Age-adjusted hospitalization risks were 7-fold higher among individuals with versus without comorbid conditions (214 vs 30/100 000, respectively). The number needed to vaccinate to prevent hospitalization was 82-fold lower for ≥75-years-olds with comorbid conditions (n = 1995), who comprised 39% of all hospitalizations, than for healthy 18–64-year-olds (n = 163 488), who comprised just 6% of all hospitalizations. Conclusions: In the context of broad-based influenza immunization programs (targeted or universal), severe outcome risks should be simultaneously examined by subtype, age, comorbidity, and vaccine status. Policymakers require such detail to prioritize promotional efforts and expenditures toward the greatest and most efficient program impact.

13 September 2024 in BMC Pulmonary Medicine
Verified
Journal Article
Open access
PDF file
CGCharles-Antoine Guay
Charles-Antoine Guay
FMFrançois Maltais
François Maltais
CBClaudia Beaudoin
Claudia Beaudoin
PCPierre-Hugues Carmichael
Pierre-Hugues Carmichael
ESElhadji Anassour Laouan Sidi
Elhadji Anassour Laouan Sidi
SPSteeve Provencher
Steeve Provencher
Background: Little is known about the trends in morbidity and mortality at the population level that followed the introduction of newer once-daily long-acting bronchodilators for COPD. The purpose of the study was to evaluate whether the availability of new bronchodilators was associated with changes in the temporal trends in severe COPD exacerbations and mortality between 2007 and 2018 in the older population with COPD; and whether this association was homogeneous across sex and socioeconomic status classes. Methods: We used an interrupted time-series and three segments multivariate autoregressive models to evaluate the adjusted changes in slopes (i.e., trend effect) in monthly severe exacerbation and mortality rates after 03/2013 and 02/2015 compared to the tiotropium period (04/2007 to 02/2013). Cohorts of individuals > 65 years with COPD were created from the nationally representative database of the Quebec Integrated Chronic Disease Surveillance System in the province of Quebec, Canada. Whether these trends were similar for men and women and across different socioeconomic status classes was also assessed. Results: There were 130,750 hospitalizations for severe exacerbation and 104,460 deaths, including 24,457 (23.4%) respiratory-related deaths, over the study period (928,934 person-years). Significant changes in trends were seen after 03/2013 for all-cause mortality (-1.14%/month;95%CI -1.90% to -0.38%), which further decreased after 02/2015 (-1.78%/month;95%CI -2.70% to -0.38%). Decreases in respiratory-related mortality (-2.45%/month;95%CI -4.38% to -0.47%) and severe exacerbation (-1,90%/month;95%CI -3.04% to -0.75%) rates were only observed after 02/2015. These observations tended to be more pronounced in women than in men and in higher socioeconomic status groups (less deprived) than in lower socioeconomic status groups (more deprived). Conclusions: The arrival of newer bronchodilators was chronologically associated with reduced trends in severe exacerbation, all-cause and respiratory-related mortality rates among people with COPD > 65 years. Our findings document population benefits on key patient-relevant outcomes in the years following the introduction of newer once-daily long-acting bronchodilators and their combinations, which were likely multifactorial. Public health efforts should focus on closing the gap between lower and higher socioeconomic status groups.

13 August 2025 in Clinical Lung Cancer
Verified
Journal Article
Open access
CGCharles-Antoine Guay
Charles-Antoine Guay
ASAlexandre Suhani
Alexandre Suhani
LPLaurie Perreault
Laurie Perreault
VMVicky Mai
Vicky Mai
ALAnne-Sophie Laliberté
Anne-Sophie Laliberté
SPSteeve Provencher
Steeve Provencher
Recent advances in cancer management may have transformed the overall prognosis of patients undergoing lung cancer resection. This study aimed to assess the changes in the long-term survival of patients undergoing surgery for lung cancer over the last 2 decades and to identify the risk factors modulating the postoperative prognosis. This single-center retrospective study included nonsmall cell lung cancer patients who underwent lung resection between 2008 and 2020. Exclusion criteria included prior lung cancer or resection, diagnosis of lung metastases, small cell lung cancers, carcinoid tumors, or benign tumors. Multivariate models analyzed determinants of short- and long-term outcomes over time. Among 2898 lung resections performed, 768 deaths (26.5%) occurred, including 25 (0.9%) in the 30-day postoperative period. Postoperative complications were observed in 1063 cases (36.7%), with 535 (18.5%) being respiratory-related. No significant improvement was observed in 30-day postoperative complications or deaths over time. Conversely, the adjusted hazard ratio (HR) for mortality was 0.72 (95% CI, 0.57-0.92) and 0.59 (95% CI, 0.45-0.78) for the in 2012-2015 and 2016-2020 periods compared to 2008-2011. In multivariate analyses, increasing age, current smoking at the time of surgery, pneumonectomy, advanced cancer stage and lower socioeconomic status were associated with worse outcomes. Over the past 2 decades, long-term survival after lung cancer resection has significantly improved, despite stable rates of early postoperative complications. Efforts to develop curative treatments for advanced stages remain crucial while public health initiatives must address socioeconomic disparities to further improve lung cancer outcomes.

13 November 2024 in medRxiv
Verified
Preprint
Open access
PDF file
SCSara Carazo
Sara Carazo
DSDanuta M Skowronski
Danuta M Skowronski
NBNicholas Brousseau
Nicholas Brousseau
CGCharles-Antoine Guay
Charles-Antoine Guay
CSChantal Sauvageau
Chantal Sauvageau
GSGaston De Serres
Gaston De Serres
Background. We evaluated mRNA COVID–19 vaccine effectiveness (VE) for the XBB.1.5 formulation against COVID–19 hospitalizations among adults aged ≥60 years during a ten–month follow–up period. Methods. We conducted a test–negative case–control study using Quebec population–based administrative data. Specimens collected from individuals aged ≥60 years tested at an acute–care hospital from October 2023 to August 2024 were considered test–positive cases if hospitalized for COVID–19, or controls if test–negative for SARS–CoV–2. Vaccination was defined by receipt of at least one mRNA XBB–vaccine (autumn or spring) dose. Multivariate logistic regression analyses estimated VE relative to several comparator groups, primarily those last–vaccinated in 2022, by subvariant predominant period (XBB, JN and KP), by time since XBB–vaccination and by number of XBB–vaccine doses (KP period). Results. Participants overall and by XBB, JN and KP periods included: 5532 (4.9%) test–positive cases (1321, 1838 and 1372, respectively) and 108473 (95.1%) test–negative controls (12881, 53414 and 28595, respectively); 14584 specimens were collected during periods of subvariant cocirculation. By subvariant period, 3322 (25.8%), 27041 (50.6%) and 15401 (53.9%) controls, respectively, were considered XBB–vaccinated. Overall VE was 30% (95%CI:24–35) and by XBB, JN or KP period: 54% (95%CI:46–62), 23% (95%CI:13–32) and 0% (95%CI:-18–15), respectively. During each subvariant period, the hospitalization risk was reduced only during the first four months post–vaccination. Conclusions. Among individuals aged ≥60 years, mRNA XBB–vaccination provided meaningful, albeit limited and short–term, protection against COVID–19 hospitalization due to XBB, JN and KP subvariants in. Better vaccines are needed to effectively reduce COVID–19 disease burden.

27 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SCSara Carazo
Sara Carazo
MOManale Ouakki
Manale Ouakki
DSDanuta M Skowronski
Danuta M Skowronski
MPMaude Paquette
Maude Paquette
NBNicholas Brousseau
Nicholas Brousseau
JPJesse Papenburg
Jesse Papenburg
Background: During the 2024-25 season, a universal infant nirsevimab program was publicly funded in Quebec, Canada. We estimated effectiveness, number-needed-to-immunize (NNI) and impact against severe respiratory syncytial virus (RSV) outcomes. Methods: We conducted a test-negative study among nirsevimab-eligible children RSV-tested during ER consultation or hospitalization between October 1 st , 2024 and March 3 st , 2025. Eligible children were healthy-term and born during the RSV season (at-birth group) or <6 months old on October 1 st (catch-up group), preterm, with high-risk conditions or living in remote regions. We estimated adjusted effectiveness by eligible group and further used 2023-24 respiratory hospitalization rates, RSV-positivity from a systematic hospital-based surveillance network, and coverage estimates to derive the NNI and tally of averted hospitalizations and ICU admissions. Results: Effectiveness analyses included 3,172 ER consultations (668 RSV-positive) and 1,758 hospitalizations (549 RSV-positive). Nirsevimab effectiveness against ER consultation, hospitalization and ICU admission was 86% (95%CI:82-90), 89% (95%CI:84-92) and 88% (95%CI:58-97), respectively. Effectiveness exceeded 80% for all eligible groups. We estimate 41 at-birth and 58 catch-up immunizations needed to avert one RSV-associated hospitalization between October and March. Applying Quebec catch-up coverage (64%) and timing (November launch), we estimate more than half of RSV-associated hospitalizations and ICU admissions were prevented, potentially increasing to more than three-quarters if catch-up coverage reached 90% by October 1 st . Conclusions: Nirsevimab is highly effective and could more substantially impact the overall burden of RSV hospitalization and ICU admission through broad and timely administration to healthy-term and high-risk infants. To inform optimal nirsevimab timing, the durability of late-season protection warrants further investigation.

2 July 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SCSara Carazo
Sara Carazo
JPJonathan Phimmasone
Jonathan Phimmasone
DSDanuta M Skowronski
Danuta M Skowronski
KGKatia Giguère
Katia Giguère
MOManale Ouakki
Manale Ouakki
GSGaston De Serres
Gaston De Serres
Background We estimated vaccine effectiveness (VE) against COVID-19 and long COVID during pre-Omicron and Omicron periods, by number of doses and prior infection history. Methods We combined survey information from a cohort of healthcare workers in Quebec, Canada, with immunization registry and laboratory administrative data. We defined COVID-19 cases as symptomatic laboratory-confirmed infections and long COVID as self-reported symptoms persisting ≥12 weeks. We assessed VE against COVID-19 and long COVID, stratified by infection history, using a test-negative design where vaccinated participants were compared to unvaccinated participants during the pre-Omicron period or to those twice vaccinated ≥6 months before laboratory testing during the Omicron period. Results Analyses included 8230 COVID-19 participants and 43361 tested specimens. During the pre-Omicron period, one- and two-dose VE was 75% (95%CI:64-83) and 95% (95%CI:84-98) against COVID-19, respectively, and 91% (95%CI:79-96) and 87% (95%CI:22-98) against long COVID, respectively. During the Omicron period, booster dose VE was 41% (95%CI:34-47) against COVID-19 and 57% (95%CI:46-66) against long COVID, waning by 6 months. Hybrid VE in vaccinated and previously infected individuals ranged 81% (95%CI:38–94) to 92% (95%CI:87–95) regardless of number of doses, prior infecting variant or median time since last immunological event up to 9 months. Conclusion COVID-19 vaccination prevented long COVID during the pre-Omicron period and reduced the risk by more than half post-Omicron. With most of the population by now both vaccinated and infected, repeated booster doses may add little incremental value against long COVID, an observation with important public health, immunization program and cost implications.